Ganaxolone
Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator — NERVOUS SYSTEM
Also known as: CCD 1042, GNX, ztalmy
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ganaxolone is a drug in the Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator class catalogued in DrugCentral. It was first approved by the FDA in 2022. Its mechanism of action is classified as GABA A Receptor Positive Modulators. DrugCentral lists 3 molecular targets, including GABRB1|GABRG2|GABRA2, GABRB1|GABRG2|GABRA3 and GABRA1|GABRB1|GABRG2. Recorded indications include Seizures associated with CDKL5 deficiency disorders.
- Drug class: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator.
- Mechanism of action: GABA A Receptor Positive Modulators.
- Molecular targets: GABRB1|GABRG2|GABRA2, GABRB1|GABRG2|GABRA3 and GABRA1|GABRB1|GABRG2 (3 listed in DrugCentral).
- Indications: Seizures associated with CDKL5 deficiency disorders.
- ATC code: N03AX27 (Other antiepileptics).
- Molecular formula: C22H36O2; molecular weight 332.53 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Seizures associated with CDKL5 deficiency disorders
Mechanism & targets
| Mechanism of action (MoA) | GABA A Receptor Positive Modulators |
|---|---|
| Established pharmacologic class | Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator |
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| GABA A receptor alpha-2/beta-1/gamma-2 | GABRB1|GABRG2|GABRA2 | modulator | EC50 7.03 |
| GABA A receptor alpha-3/beta-1/gamma-2 | GABRB1|GABRG2|GABRA3 | modulator | EC50 6.91 |
| GABA A receptor alpha-1/beta-1/gamma-2 | GABRA1|GABRB1|GABRG2 | modulator | EC50 6.67 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2023-07-26 | EMA | — | Marinus Pharmaceuticals Emerald Limited | Yes |
| 2022-03-18 | FDA | — | MARINUS PHARMA INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N03AX27 | NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: CDKL5 · Testing Required
- FDA label: CDKL5 · Testing Required
- HCSC label
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Change in seizure presentation | 199.9 |
| Product dose omission issue | 101.8 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Ganaxolone is on its molecule page.
| Molecular formula | C22H36O2 |
|---|---|
| Molecular weight | 332.53 g/mol |
| CAS number | 38398-32-2 |
| InChIKey | PGTVWKLGGCQMBR-FLBATMFCSA-N |
| PubChem CID | 6918305 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ganaxolone used for?
DrugCentral lists the following indications for Ganaxolone: Seizures associated with CDKL5 deficiency disorders.
How does Ganaxolone work?
Ganaxolone is classified as GABA A Receptor Positive Modulators; its molecular targets in DrugCentral include GABRB1|GABRG2|GABRA2 (modulator), GABRB1|GABRG2|GABRA3 (modulator) and GABRA1|GABRB1|GABRG2 (modulator).
When was Ganaxolone first approved?
Ganaxolone was first approved by the FDA in 2022.
What drug class does Ganaxolone belong to?
Ganaxolone is in the Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator class.
What is the chemical formula of Ganaxolone?
Ganaxolone has the molecular formula C22H36O2 and a molecular weight of 332.53 g/mol.
Browse: all drugs starting with G · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5508 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1568698 — compound record and bioactivity
- PubChem CID 6918305 — chemical identifiers
- DrugBank DB05087 — drug record
- FDA UNII 98WI44OHIQ — substance identity
- DailyMed: FDA labels for Ganaxolone — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.